A Phase 2 interventional study of belimumab in Rheumatoid Arthritis, sponsored by Human Genome Sciences Inc.. Terminated at 48 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-08-07.
Sponsored by Human Genome Sciences Inc. (part of GlaxoSmithKline) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in Arthritis, Rheumatoid by GlaxoSmithKline — 1 open to participants now, 1 under way, none of them phase 3. Arthritis, Rheumatoid · GlaxoSmithKline.
Among the 44 studies in Arthritis, Rheumatoid by GlaxoSmithKline, this one is the 11th largest by enrollment of the 40 interventional ones that give a count, is one of 8 that started in 2005, is one of 17 in phase 2, and was the 18th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →1 of the 44 studies in Arthritis, Rheumatoid by GlaxoSmithKline is open now, in 9 countries. Recruiting first, the newest first:
GlaxoSmithKline · Sites in Argentina, Brazil, France and 6 more countries
Ages 18–70
By country, each count listing its studies:
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 19 · Phase 3 8
First in 2001; this study’s year is marked. 8 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 155 is above the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 52 across the 40 interventional studies, 32 across the 3 observational. Of the 40 that completed or were terminated, 17 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Human Genome Sciences Inc., one of the names counted as GlaxoSmithKline. Under that name alone:
Human Genome Sciences Inc. is the lead sponsor of 23 studies on the registry; none are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 44 studies in Arthritis, Rheumatoid by GlaxoSmithKline, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a continuation trial of LymphoStat-B™ to evaluate the long-term safety in subjects with Rheumatoid Arthritis that completed study LBRA01 and benefitted from treatment.
This is a multi-center, open label, continuation trial of LymphoStat-B™ in Rheumatoid Arthritis (RA) subjects who achieved at least an ACR20 response in the Phase 2 study LBRA01 (NCT00071812).
Primary Inclusion Criteria:
Primary Exclusion Criteria:
Used prohibited medications during their participation in LBRA01. These medications include the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: belimumab
IV 10mg/kg Q28 days
Also known as: LymphoStat-B™
To Evaluate the Long-term Safety of LymphoStat-B™ in Subjects With RA.
SEE ALSO ADVERSE EVENT (AE) RESULTS SECTION.
Time frame: Up to 5 years
The Efficacy Endpoints Will Include Long-term ACR Responses, DAS28 Response, C-reactive Protein (CRP), Erythrocyte Sedimentation Rate (ESR), and Rheumatoid Factor (RF).
NOT ANALYZED
Time frame: up to 5 Years
| Milestone | Belimumab 10 mg/kg |
|---|---|
| Started | 155 |
| Received at least 1 dose belimumab | 153 |
| Completed | 85 |
| Not completed | 70 |
| Withdrew: Withdrawal by subject | 18 |
| Withdrew: Adverse event | 9 |
| Withdrew: Lack of efficacy | 31 |
| Withdrew: Lack of compliance | 5 |
| Withdrew: Other | 5 |
| Withdrew: Did not receive belimumab in lbra99 | 2 |
SEE ALSO ADVERSE EVENT (AE) RESULTS SECTION.
| Particpants | Belimumab 10 mg/kg |
|---|---|
| Number of subjects with at least 1 AE | 148 |
| Number of subjects with at least 1 Non-Serious AE | 144 |
| Number of subjects with at least 1 Serious AE | 47 |
| Number of subjects with an AE resulting in death | 3 |
NOT ANALYZED
Results for this outcome have not been posted.
Collected over Up to 5 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Belimumab 10 mg/kg | — | 47/153 (30.7%) | 144/153 (94.1%) |
| Event | Belimumab 10 mg/kg |
|---|---|
| OsteoarthritisMusculoskeletal and connective tissue disorders | 6/153 |
| AnaemiaBlood and lymphatic system disorders | 3/153 |
| Angina pectorisCardiac disorders | 3/153 |
| PneumoniaInfections and infestations | 3/153 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/153 |
| Coronary artery diseaseCardiac disorders | 2/153 |
| Non-cardiac chest painGeneral disorders | 2/153 |
| GastroenteritisInfections and infestations | 2/153 |
| PyelonephritisInfections and infestations | 2/153 |
| DehydrationMetabolism and nutrition disorders | 2/153 |
| Event | Belimumab 10 mg/kg |
|---|---|
| ArthralgiaMusculoskeletal and connective tissue disorders | 66/153 |
| Upper respiratory tract infectionInfections and infestations | 53/153 |
| SinusitisInfections and infestations | 39/153 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 36/153 |
| BronchitisInfections and infestations | 35/153 |
| Back painMusculoskeletal and connective tissue disorders | 31/153 |
| Oedema peripheralGeneral disorders | 28/153 |
| CoughRespiratory, thoracic and mediastinal disorders | 27/153 |
| DiarrhoeaGastrointestinal disorders | 24/153 |
| Joint swellingMusculoskeletal and connective tissue disorders | 24/153 |
| Age Continuous(years) | Belimumab 10 mg/kg |
|---|---|
| Mean | 51.1 ± 8.9 |
| Sex: Female, Male(Participants) | Belimumab 10 mg/kg |
|---|---|
| Female | 118 |
| Male | 35 |
The record gives a start of Jan 2005, a primary completion of Nov 2009 and a completion of Nov 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2011, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Belimumab